Nektar Therapeutics Inc (NKTR)

23.38
0.96 4.28
NASDAQ : Health Care
Prev Close 22.42
Open 22.00
Day Low/High 21.50 / 23.44
52 Wk Low/High 9.16 / 17.55
Volume 2.34M
Avg Volume 1.71M
Exchange NASDAQ
Shares Outstanding 153.83M
Market Cap 3.47B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Rev's Forum: Don't Just Sit There, Do Something!

Rev's Forum: Don't Just Sit There, Do Something!

Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

Here's how to trade six of the most active names on the market this afternoon.

Biotechs Remain the Best Place For Stock Picking

Biotechs Remain the Best Place For Stock Picking

Biotech companies show more energy than the rest of the market Monday.

Biotech Premarket Movers: CytomX, Aevi, Esperion

Biotech Premarket Movers: CytomX, Aevi, Esperion

CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.

NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain

NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain

NKTR-181 Significantly Reduced Pain in Patients with Moderate to Severe Chronic Low Back Pain

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Finding the stocks that have changed direction.

Nektar Therapeutics Announces Upcoming Presentations At The American Association For Cancer Research Annual Meeting

Nektar Therapeutics Announces Upcoming Presentations At The American Association For Cancer Research Annual Meeting

Five Data Presentations Will Showcase Nektar's Immuno-oncology Candidates, NKTR-214 and NKTR-255

Interesting NKTR Put And Call Options For March 17th

Interesting NKTR Put And Call Options For March 17th

Investors in Nektar Therapeutics saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

First Week of NKTR August 2017 Options Trading

First Week of NKTR August 2017 Options Trading

Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Nektar Therapeutics Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting

Nektar Therapeutics Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting

Single-agent, anti-tumor activity observed in 7/18 evaluable patients with solid tumors, including one unconfirmed partial response per RECIST 1.1

Nektar To Hold Investor & Analyst Event At 2016 Society For Immunotherapy Of Cancer Annual Meeting

Nektar To Hold Investor & Analyst Event At 2016 Society For Immunotherapy Of Cancer Annual Meeting

Data from Phase 1 dose-escalation trial of NKTR-214 to be presented by lead clinical investigators

Nektar Therapeutics Announces Upcoming Presentations At The 2016 Society For Immunotherapy Of Cancer Annual Meeting

Nektar Therapeutics Announces Upcoming Presentations At The 2016 Society For Immunotherapy Of Cancer Annual Meeting

Five data presentations will showcase Nektar's immuno-oncology candidates, NKTR-214 and NKTR-255

Short Interest Jumps 12.5% For NKTR

Short Interest Jumps 12.5% For NKTR

The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 1,041,247 share increase in total short interest for Nektar Therapeutics , to 9,398,731, an increase of 12.46% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.

Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing

Nektar Therapeutics (NKTR) Stock Falls on Public Offering Pricing

Nektar Therapeutics (NKTR) said on Wednesday that it would sell 13 million shares of common stock at $13.50 each.

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.